Oral Combination of Cyclophosphamide, Uracil plus Tegafur and Estramustine for Hormone-Refractory Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0232|60|1|49-54

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.1, 2000-12, pp. : 49-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

By Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Journal of Infection and Chemotherapy, Vol. 16, Iss. 3, 2010-06 ,pp. : 200-205

Springer Publishing Company

Access to resources Recommend Favorite

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 2-9

Karger

Access to resources Recommend Favorite

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 223-228

Karger

Access to resources Recommend Favorite

TREATMENT WITH PREDNISOLONE OF HORMONE-REFRACTORY PROSTATE CANCER

By Fuse H.   Nozaki T.   Fujiuchi Y.   Mizuno I.   Nagakawa O.   Okumura A.  

Archives of Andrology, Vol. 52, Iss. 1, 2006-01 ,pp. : 35-38

Informa Healthcare

Access to resources Recommend Favorite

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 70, Iss. 1, 2003-02 ,pp. : 1-14

Karger

Access to resources Recommend Favorite